Recombinant antithrombin attenuates pulmonary inflammation following smoke inhalation and pneumonia in sheep

Critical Care Medicine

Volumn 31, Issue 2, 2003, Pages 577-583

  Murakami, Kazunori ^a   McGuire, Roy ^a   Cox, Robert A ^a   Jodoin, Jeffrey M ^a   Schmalstieg, Frank C ^a   Traber, Lillian D ^a   Hawkins, Hal K ^a   Herndon, David N ^a   Traber, Daniel L ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Acute lung injury; Adult respiratory distress syndrome; Cardiovascular; Histology; Pseudomonas; Pulmonary; Recombinant antithrombin; Sepsis; Smoke inhalation

Indexed keywords

NITRIC OXIDE; RECOMBINANT ANTITHROMBIN III;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; FEMALE; HISTOLOGY; INFLAMMATION; LEUKOCYTE COUNT; LUNG BURN; LUNG WEIGHT; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SHEEP; TREATMENT OUTCOME; URINE VOLUME;

ANIMALS; ANTITHROMBINS; FEMALE; PNEUMONIA; RECOMBINANT PROTEINS; SHEEP; SMOKE INHALATION INJURY;

EID: 0037324153     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000050444.52531.08     Document Type: Article

References (33)

1. Uchiba M, Okajima K: Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: Novel biological activity of AT III. Semin Thromb Hemost 1997; 23:583-590
2. Opal SM: Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000; 28:S34-S37
3. Fourrier F, Jourdain M, Tournoys A: Clinical trial results with antithrombin III in sepsis. Crit Care Med 2000; 28:S38-S43
4. Eisele B, Lamy M, Thijs LG, et al: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-672
5. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
6. Minnema MC, Chang AC, Jansen PM, et al: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2001; 95:1117-1123
7. Rue LW, Cioffi WG, Mason AD Jr, et al: The risk of pneumonia in thermally injured patients requiring ventilatory support. J Burn Care Rehabil 1995; 16:262-268
8. Linares HA: A report of 115 consecutive autopsies in burned children: 1966-80. Burns Incl Therm Inj 1982; 8:263-270
9. Herndon DN, Adams T Jr, Traber LD, et al: Inhalation injury and positive pressure ventilation in a sheep model. Circ Shock 1984; 12:107-113
10. Kimura R, Traber LD, Herndon DN, et al: Increasing duration of smoke exposure induces more severe lung injury in sheep. J Appl Physiol 1988; 64:1107-1113
11. Newman JH, Loyd JE, English DK, et al: Effects of 100% oxygen on lung vascular function in awake sheep. J Appl Physiol 1983; 54:1379-1386
12. Edmunds T, Van Patten SM, Pollock J, et al: Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91:4561-4571
13. Narimanbekov IO, Rozycki H J: Effect of IL-1 blockade on inflammatory manifestations of acute ventilator-induced lung injury in a rabbit model. Exp Lung Res 1995; 21:239-254
14. Sakurai H, Johnigan R, Kikuchi Y, et al: Effect of reduced bronchial circulation on lung fluid flux after smoke inhalation in sheep. J Appl Physiol 1998; 84:980-986
15. Goodnight SH Jr, Schaeffer JL, Sheth K: Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assays. Am J Clin Pathol 1980; 73:639-647
16. Dickneite G: Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24:61-69
17. Uchiba M, Okajima K, Murakami K, et al; Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270:L921-L930
18. Uchiba M, Okajima K, Murakami K, et al: Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats. Thromb Res 1995; 80:201-228
19. Souter PJ, Thomas S, Hubbard AR, et al: Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29:134-139
20. Kaneider NC, Egger P, Dunzendorfer S, et al: Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001; 287:42-46
21. Gunther A, Mosavi P, Heinemann S, et al: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am Respir Crit Care Med 2000; 161:454-462
22. Gross TJ, Simon RH, Sitrin RG: Tissue factor procoagulant expression by rat alveolar epithelial cells. Am J Respir Cell Mol Biol 1992; 6:397-403
23. Sitrin RG, Brubaker PG, Shellito JE, et al: The distribution of procoagulant and plasminogen activator activities among density fractions of normal rabbit alveolar macrophages. Am Rev Respir Dis 1986; 133:468-472
24. Drake TA, Cheng J, Chang A, et al: Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142:1458-1470 [published erratum appears in Am J Pathol 1993; 143:649]
25. Bertozzi P, Astedt B, Zenzius L, et al: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322:890-897
26. Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24:33-44
27. Seeger W, Elssner A, Gunther A, et al: Lung surfactant phospholipids associate with polymerizing fibrin: Loss of surface activity. Am J Respir Cell Mol Biol 1993; 9:213-220 [published erratum appears in Am J Respir Cell Mol Biol 1993; 9:following 462]
28. Ravanat C, Freund M, Dol F, et al: Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinol 1995; 6:446-455
29. Pratt CW, Church FC: Antithrombin; Structure and function. Semin Hematol 1991; 28:3-9
30. Niessen RW, Lamping RJ, Jansen PM, et al: Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78:1088-1192
31. Murakami K, McGuire R, Cox RA, et al: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock, In Press
32. Theissen JL, Loick HM, Curry BB, et al: Time course of hypoxic pulmonary vasoconstriction after endotoxin infusion in unanesthetized sheep. J Appl Physiol 1991; 70:2120-2125
33. Fischer SR, Deyo DJ, Bone HG, et al: Nitric oxide synthase inhibition restores hypoxic pulmonary vasoconstriction in sepsis. Am J Respir Crit Care Med 1997; 156:833-839